FDA approves new drug for Alzheimer’s disease: ‘Meaningful results’

UCSF clinical professor of medicine Dr. Dean Ornish joins ‘Fox & Friends’ to discuss his clinical study offering a better quality of life to Alzheimer's patients. The U.

S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease . Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease, according to a press release from the company.

Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology. EXPERIMENTAL ALZHEIMER’S DRUG GETS FDA ADVISORY PANEL'S THUMBS-UP: ‘PROGRESS IS HAPPENING’ This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function — with evidence to support stopping therapy when amyloid plaques are removed, the release stated. The U.

S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease. (iStock) "Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options," said Anne White, executive vice president and president of Lilly Neuroscience, Eli Lilly and Company , in the release.

"We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership .